Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage company Reiterating full year 2022 total revenue guidance of between $4 and $5 billion Continued label expansion including primary, booster and adolescent authorizations and new shipments of Nuvaxovid™ into European Union, Canada, South Korea, Australia …

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights Read More »